Ionis won an FDA label expansion for its antisense therapy Tryngolza (landing an additional indication aimed at severe hypertriglyceridemia and related pancreatitis risk). The company said the approval expands its commercial opportunity for the drug, which has become a prominent example of how antisense platforms can create targeted leverage in lipid disorders. For prescribers and payers, label expansion can accelerate uptake by clarifying who qualifies for treatment—especially in high-risk patients where triglyceride levels drive acute pancreatitis and recurrent events.